Mykofenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate mofetil selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for de novo synthesis of guanosine nucleotides. This inhibition reduces the proliferation of activated T‑ and B‑lymphocytes, thereby suppressing the immune mechanisms that lead to organ rejection.

The specific dose and infusion rate of Mykofenolatmofetil Accord are determined by the prescribing physician based on the patient’s transplant type, weight, renal function and other clinical factors. Dosing should always follow the individualised regimen set by the treating clinician.

Mykofenolatmofetil Accord is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Mykofenolatmofetil Accord (mycophenolate mofetil) differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcium‑dependent signaling. This distinct mechanism often results in a different side‑effect profile, with less nephrotoxicity but higher rates of gastrointestinal upset and bone‑marrow suppression.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, inspect the solution for particulates or discoloration and use aseptic technique as recommended for intravenous preparations.

Mykofenolatmofetil Accord is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of qualified healthcare professionals. The infusion rate and duration are set by the prescribing clinician according to the patient’s therapeutic plan.

Serious risks include severe infections (including opportunistic pathogens), malignancies such as post‑transplant lymphoproliferative disorder, profound neutropenia or leukopenia, hepatic toxicity, and rare neurological complications like progressive multifocal leukoencephalopathy. Patients should be monitored closely for signs of infection or abnormal laboratory values.

Mykofenolatmofetil Accord is contraindicated in patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation. It should also be avoided in pregnant women unless absolutely necessary, and in individuals with uncontrolled severe infections or active malignancy without appropriate oncologic supervision.